<p>If coronavirus vaccinations are rolled out widely, life could return to "normal" by next winter, one of the scientists behind the front-running coronavirus vaccine told British television on Sunday.</p>.<p>Ugur Sahin, the Turkish co-founder of German firm BioN, told the BBC's The Andrew Marr Show that "this winter will be hard" without any major impact from vaccinations.</p>.<p>Together with US giant Pfizer, BioN is developing the leading candidate in the worldwide chase for a vaccine.</p>.<p>"If all goes well, we will start to deliver the vaccine at the end of this year, or beginning of next year," Sahin said.</p>.<p>"Our goal is to deliver more than 300 million doses by April next year, which could already have an impact," he said.</p>.<p>The infection rate will then go down in summer, he predicted, adding that it is essential that there is a high takeup of the vaccination by autumn.</p>.<p>"I'm confident that this will happen, he said.</p>.<p>A number of vaccination companies are working to increase the supply, he said: "so we could have a normal winter next (year)."</p>.<p>Sahin and his wife Ozlem Tureci founded BioNTech in the western German city of Mainz in 2008.</p>.<p>Having identified promising vaccine blueprints, the company formed a partnership in March with American pharmaceutical giant Pfizer.</p>.<p>The announcement on Monday that their vaccine was more than 90 per cent effective in trials led news bulletins around the world and sent stock markets and hopes to soar.</p>.<p>BioNTech is now worth $25.8 billion (21.8 billion euros), more than Germany's largest lender Deutsche Bank.</p>
<p>If coronavirus vaccinations are rolled out widely, life could return to "normal" by next winter, one of the scientists behind the front-running coronavirus vaccine told British television on Sunday.</p>.<p>Ugur Sahin, the Turkish co-founder of German firm BioN, told the BBC's The Andrew Marr Show that "this winter will be hard" without any major impact from vaccinations.</p>.<p>Together with US giant Pfizer, BioN is developing the leading candidate in the worldwide chase for a vaccine.</p>.<p>"If all goes well, we will start to deliver the vaccine at the end of this year, or beginning of next year," Sahin said.</p>.<p>"Our goal is to deliver more than 300 million doses by April next year, which could already have an impact," he said.</p>.<p>The infection rate will then go down in summer, he predicted, adding that it is essential that there is a high takeup of the vaccination by autumn.</p>.<p>"I'm confident that this will happen, he said.</p>.<p>A number of vaccination companies are working to increase the supply, he said: "so we could have a normal winter next (year)."</p>.<p>Sahin and his wife Ozlem Tureci founded BioNTech in the western German city of Mainz in 2008.</p>.<p>Having identified promising vaccine blueprints, the company formed a partnership in March with American pharmaceutical giant Pfizer.</p>.<p>The announcement on Monday that their vaccine was more than 90 per cent effective in trials led news bulletins around the world and sent stock markets and hopes to soar.</p>.<p>BioNTech is now worth $25.8 billion (21.8 billion euros), more than Germany's largest lender Deutsche Bank.</p>